Royalty Pharma plc (RPRX) Stock Price, News, Quote & History

Find the latest Royalty Pharma plc (RPRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ... Loading Chart for RPRX. DELL. Date: …

19%
OFF

RPRX Stock Price & Charts | Royalty Pharma

2 weeks from now

In depth view into RPRX (Royalty Pharma) stock including the latest price, news, dividend history, earnings information and financials. Royalty Pharma PLC (RPRX) 25.84 +0.05 ( +0.19% ) …

ycharts.com

98%
OFF

Royalty Pharma Stock Price | RPRX Stock Quote, News, And History ...

2 weeks from now

6 days ago · The low in the last 52 weeks of Royalty Pharma stock was 24.05. According to the current price, Royalty Pharma is 108.98% away from the 52-week low. What was the 52-week …

businessinsider.com

16%
OFF

Royalty Pharma: Key Strategic Updates To Be Priced In

2 weeks from now

1 hour ago · Following our Strong Buy suggestion in early November 2024, Royalty Pharma plc (NASDAQ:RPRX) stock price increased by more than 16%, with a clear outperformance over …

seekingalpha.com

$29.49
OFF

Here’s Why Royalty Pharma Plc (RPRX) Led This Week’s Rally - MSN

2 weeks from now

Royalty Pharma plc (NASDAQ:RPRX) Royalty Pharma plc (NASDAQ:RPRX) saw its share price increase by 14.26 percent to end at $29.49 apiece versus the $25.81 posted the week prior, …

msn.com

$1.13
OFF

Royalty Pharma (RPRX) Earnings Date And Reports 2025

2 weeks from now

Albemarle Stock Call Options Surge: What It Means for Lithium; ... Royalty Pharma (NASDAQ:RPRX) has a recorded net income of $1.13 billion. RPRX has generated $1.93 …

marketbeat.com

$3000
OFF

Royalty Pharma Plc Announces An Equity Buyback For $3,000 …

2 weeks from now

5 days ago · Royalty Pharma plc announces a share repurchase program. Under the program, the company will repurchase up to $3,000 million worth of its shares. ... Goldman Sachs Adjusts …

marketscreener.com

FAQs about Royalty Pharma plc (RPRX) Stock Price, News, Quote & History Coupon?

What is the market capitalization of Royalty Pharma plc (RPRX)?

The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market. Find the latest Royalty Pharma plc (RPRX) stock quote, history, news and other vital information to help you with your stock trading and investing. ...

Is Royalty Pharma plc (RPRX) a good stock to buy?

Royalty Pharma plc (NASDAQ:RPRX) said its decision followed investors’ feedback that the current structure made it difficult to invest in the healthcare firm, and shifting to internal management could enhance the company’s valuation over time. Overall RPRX ranks 8th on our list of the firms that led this week's rally. ...

What is the 12-month price forecast for Royalty Pharma plc (RPRX)?

The 12-month stock price forecast is $41.67, which is an increase of 67.75% from the latest price. NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: ...

Why is RPRX trading at a 47% discount?

RPRX is trading at a 47% discount. Royalty Pharma’s portfolio includes market-leading therapies for a wide range of diseases, enabling stable future royalty streams and high returns on investments over the next decade. Underperformance of key portfolio products due to major regulatory changes could put pressure on Royalty Pharma’s cash flows. ...

How did Royalty Pharma (RPRX) perform in the quarter?

Royalty Pharma plc (NASDAQ:RPRX) announced its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating the consensus estimate of $0.95 by $0.01. The biopharmaceutical company earned $537 million during the quarter, compared to analyst estimates of $600.83 million. ...

Is RPRX (RPRX) a good stock to buy?

Plus, the company is currently a Zacks Rank #3 (Hold) stock. Looking at RPRX's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 2 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well. ...